Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Where Can You Report your Adverse Drug Reactions or Adverse Events Following Immunization

 
Where Can You Report your Adverse Drug Reactions or Adverse Events Following Immunization
 

This section provides a comprehensive overview of the procedures and tools available to Healthcare Professionals, Market Authorization Holders and the General Public to report adverse events associated with medicinal products and vaccines in Lebanon.
 
How to report

You can send the case reports using the following tools:
 
  1. For Healthcare Professionals and the Public
The Lebanese National Pharmacovigilance Program has adapted two user-friendly tools: one for Adverse Drug Reactions (Vigimobile e-Reporting e-Form) and another for reporting Adverse Events Following Immunization (Vigimobile e-Form). Both tools may be accessed by healthcare professionals and the general public.
 
  1. The VigiMobile e-Form and e-Reporting e-Form:
The VigiMobile e-Form and e-Reporting e-Form are the latest tools launched in January 2025 by the Lebanese National Pharmacovigilance Program. These digital platforms were introduced to enhance the reporting process, with the e-Reporting e-Form designed for Adverse Drug Reactions (ADRs) and the VigiMobile e-Form specifically for Adverse Events Following Immunization (AEFIs).

How to Download on Android Phones
 
  1. Scan the QR Code by pressing the link
  2. Click the three dots in the top-right corner
  3. Choose Install app
  4. VigiMobile e-Form/e-Reporting e-Form now appears as an app
 
How to Download on Apple IOS Phones
 
  1. Scan the QR Code by pressing the link
  2. Click on the share button
  3. Add VigiMobile to the home screen
  4. VigiMobile e-Form/e-Reporting e-Form now appears as an app

How to Download on Windows
  1. Press on the link
  2. Install from the Browser menu
  3. VigiMobile e-Form/e-Reporting e-Form is now installed 
 
Scan QR Codes to Report:
  1. ADRs Following Medication Use
  1. AEFIs Following Vaccine Use
Or use the following link: LNPVP: e-Reporting eForm Or use the following link: LNPVP: VigiMobile eForm
 
  1. Direct Contact with the Lebanese National Pharmacovigilance Program:
You may contact the Lebanese National Pharmacovigilance Program through:
  • Email Address:
  • Phone number of the Quality Assurance of Pharmaceutical Products Program: 01-830254   
 
  1.  For Market Authorization Holders:
Based on the Ministerial Resolution MR #181 issued in 2021, MAHs should adhere to the internationally agreed ICH guidelines and standards and send the reports in XML format as specified in ICH E2B (R2 or R3) guidelines

(https://www.moph.gov.lb/userfiles/files/Quality%26Safety/PharmacovigilanceSystemInLebanon/Karar%20181-2021.pdf).

All XML files should be sent to the following emails: pv@moph.gov.lb, and pv.moph@gmail.com.
 
As for what to report or report type, you can refer to Module VI:
https://moph.gov.lb/en/Pages/4/44742/pharmacovigilance-system-lebanon#/en/view/70479/lebanese-guideline-on-good-pharmacovigilance-practices-lgvp-
 
    ...
    153
    ...
ATC Name B/G Ingredients Dosage Form Price
C10AA07 ROXARDIO G Rosuvastatin (calcium) - 20mg 20mg Tablet, film coated 720,525 L.L
M01AH05 CLINTON G Etoricoxib - 90mg 90mg Tablet, film coated 454,219 L.L
C05CA53 DAFLON B Hesperidin - 50mg, Diosmin - 450mg Tablet, film coated 627,574 L.L
C09CA08 OLMETEC B Olmesartan medoxomil - 10mg 10mg Tablet, film coated 710,893 L.L
C10AA07 SINLIP G Rosuvastatin (calcium) - 20mg 20mg Tablet, film coated 563,070 L.L
M01AH05 CLINTON G Etoricoxib - 90mg 90mg Tablet, film coated 1,280,682 L.L
C05CA53 DAFLON B Hesperidin - 50mg, Diosmin - 450mg Tablet, film coated 1,191,988 L.L
C09CA08 VOTUM B Olmesartan medoxomil - 10mg 10mg Tablet, film coated 753,896 L.L
J01MA17 KINODROX B Prulifloxacin - 600mg 600mg Tablet, film coated 1,407,835 L.L
M01AH05 CONSORT G Etoricoxib - 90mg 90mg Tablet, film coated 338,648 L.L
N05AE05 LURABIL G Lurasidone - 20mg 20mg Tablet, film coated 2,535,831 L.L
C05CA53 DAFLON B Hesperidin - 100mg, Diosmin - 900mg Tablet, film coated 1,256,493 L.L
C09CA08 VOTUM B Olmesartan medoxomil - 10mg 10mg Tablet, film coated 753,896 L.L
C10AA07 UBSATOR-CA G Rosuvastatin (calcium) - 20mg 20mg Tablet, film coated 499,142 L.L
M01AH05 COXIFLAM G Etoricoxib - 90mg 90mg Tablet, film coated 1,293,928 L.L
N05AE05 LAROZA G Lurasidone - 40mg 40mg Tablet, film coated 5,548,726 L.L
A11CC05 BIODAL G Vitamin D3 - 50,000IU 50,000IU Tablet, film coated 1,110,014 L.L
C09CA08 OLMENOR G Olmesartan medoxomil - 10mg 10mg Tablet, film coated 526,786 L.L
C10AA07 CRESTOR B Rosuvastatin (calcium) - 40mg 40mg Tablet, film coated 804,962 L.L
M01AH05 ETOXA G Etoricoxib - 90mg 90mg Tablet, film coated 1,293,928 L.L
N05AE05 LURABIL G Lurasidone - 40mg 40mg Tablet, film coated 2,535,831 L.L
C02KX01 BOSENTAN ARROW G Bosentan (monohydrate) - 62.5mg 62.5mg Tablet, film coated L.L
C05CX TANAKAN B Ginkgo biloba - 40mg 40mg Tablet, film coated 600,698 L.L
C09CA08 OLMETEC B Olmesartan medoxomil - 20mg 20mg Tablet, film coated 888,280 L.L
M01AH05 ETOXA G Etoricoxib - 90mg 90mg Tablet, film coated 431,309 L.L
N05AE05 LAROZA G Lurasidone - 80mg 80mg Tablet, film coated 5,548,726 L.L
N06AX26 BRINTELLIX B Vortioxetine - 5mg 5mg Tablet, film coated 2,592,272 L.L
C02KX01 BOSENTAN ARROW G Bosentan (monohydrate) - 125mg 125mg Tablet, film coated L.L
C05CX TANAKAN B Ginkgo biloba - 40mg 40mg Tablet, film coated 1,662,333 L.L
C09CA08 VOTUM B Olmesartan medoxomil - 20mg 20mg Tablet, film coated 954,128 L.L
    ...
    153
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025